# Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Source: https://onco.cc/trials/nct06992609/  
OnCo record `nct06992609` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. is a phase 3 interventional study registered as NCT06992609 by AstraZeneca, with 68 participants enrolled, started 2025-09-15 and due to reach its primary completion in 2029-06-30. Interventions recorded: Durvalumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06992609
- Phase: 3
- Setting: A Phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN).
- Sponsor: AstraZeneca
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT06992609: https://clinicaltrials.gov/study/NCT06992609

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06992609.json